PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
14.76%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
14.50%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
13.53%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
13.53%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
23.16%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
-41.67%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-40.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
103.97%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
104.39%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
126.49%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
418.36%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-5.67%
Negative 10Y revenue/share CAGR while AVGO stands at 416.86%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-5.67%
Negative 5Y CAGR while AVGO stands at 134.28%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-5.67%
Negative 3Y CAGR while AVGO stands at 62.33%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
414.93%
10Y OCF/share CAGR at 50-75% of AVGO's 580.47%. Martin Whitman might fear a structural deficiency in operational efficiency.
414.93%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
414.93%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
45.15%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
45.15%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
45.15%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
7.87%
Below 50% of AVGO's 862.23%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
7.87%
Below 50% of AVGO's 165.61%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.87%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.19%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
23.34%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.26%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-37.80%
We have a declining book value while AVGO shows 5.15%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-28.87%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
12.96%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
20.55%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.